Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 2 11:57 ET
Express News | HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $21
Moomoo 24/7Apr 2 11:47 ET
Kala Pharmaceuticals Price Target Maintained With a $15.00/Share by Oppenheimer
Kala Pharmaceuticals Price Target Maintained With a $15.00/Share by Oppenheimer
Dow JonesApr 1 09:33 ET
Express News | Oppenheimer Reiterates Outperform on Kala Bio, Maintains $15 Price Target
Moomoo 24/7Apr 1 09:23 ET
Kala Pharmaceuticals GAAP EPS of -$3.18 Beats by $0.44
Seeking AlphaMar 29 08:34 ET
KALA BIO 4Q Loss/Shr $3.18 >KALA
KALA BIO 4Q Loss/Shr $3.18 >KALA
Dow JonesMar 29 08:00 ET
Press Release: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 202
Dow JonesMar 29 08:00 ET
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resou
Kala PharmaceuticalsMar 29 00:00 ET
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovativ
Kala PharmaceuticalsFeb 26 00:00 ET
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovativ
Kala PharmaceuticalsFeb 6 00:00 ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersPHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutic
BenzingaDec 5, 2023 12:31 ET
Kala Pharmaceuticals Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.
Kala Pharmaceuticals Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.
Dow JonesNov 17, 2023 06:59 ET
HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $22
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $24 to $22.
BenzingaNov 17, 2023 06:49 ET
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating
MT NewswiresNov 14, 2023 07:03 ET
Kala Pharmaceuticals GAAP EPS of -$3.41 Misses by $1.26
Seeking AlphaNov 13, 2023 14:34 ET
Kala Bio: Q3 Earnings Insights
Kala Bio (NASDAQ:KALA) reported its Q3 earnings results on Monday, November 13, 2023 at 08:00 AM.Here's what investors need to know about the announcement.EarningsKala Bio missed estimated earnings by
BenzingaNov 13, 2023 08:30 ET
Kala Pharmaceuticals Q3 EPS $(3.41) Misses $(2.15) Estimate
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate of $(2.15) by 58.6 percent. This is a 61.77 percent increase over losses o
BenzingaNov 13, 2023 08:11 ET
KALA BIO Enrollment Ongoing in CHASE Phase 2b Clinical Trial of KPI-012 for PCED; Topline Data Expected in 2H 2024 >KALA
KALA BIO Enrollment Ongoing in CHASE Phase 2b Clinical Trial of KPI-012 for PCED; Topline Data Expected in 2H 2024 >KALA
Dow JonesNov 13, 2023 08:06 ET
KALA BIO 3Q Loss/Shr $3.41 >KALA
KALA BIO 3Q Loss/Shr $3.41 >KALA
Dow JonesNov 13, 2023 08:00 ET
Press Release: KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update -- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- --
Dow JonesNov 13, 2023 08:00 ET
No Data
No Data